Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner  and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Nintedanib
Nintedanib

Maintaining Treatment Adherence in CTD-ILD

10/09/2024  |  Author: Boehringer Ingelheim

Document ID: PC-MY-103930

Expert View

COLL4B||Perspectives on antifibrotic treatment in CTD-ILD & management AE
COLL4B||Perspectives on PF in CTD-ILDs & tips for ILD identification
COLL4B||ILD Masterclass 2024 Post-Event Newsletter
COLL4B||Nintedanib in RA-ILD: Insights from the INBUILD Trial
COLL4B||When to Start Treatment for SSc-ILD
COLL4B||Maintaining Treatment Adherence in CTD-ILD
COLL4B||Nintedanib's Role in CTD-ILD Management
COLL4B||Monitoring Patients with CTD-ILD: Best Practices
COLL4B||Importance of Early Referral in CTD-ILD
COLL4B||ILD Care: Insights from an ILD Nurse Specialist
COLL4B||“Latest Update on CTD-ILD Management” by Dr. Voon Ong
FSIN||ILD Talk: The future of treatment for HP
FSIN||ILD Talk: The experts’ practical experience with OFEV® (nintedanib)
FSIN||ILD Talk: How to treat progressive, fibrotic HP
FSIN||ILD Talk: How to monitor patients with HP for progression and identify PPF early
FSIN||ILD Talk: What are the treatment options for patients with HP
FSIN||ILD Talk: Tips for differentiating HP from idiopathic pulmonary fibrosis
FSIN||Optimizing treatment of patients with PF-ILD with patient case study- Expert Lecture
FSIN||Why even wait until there is 10% relative FVC decline? – Physician Perspective video snippet
FSIN||Rationale for early antifibrotic treatment in PF-ILD Video snippet
FSIN||How to Identify Progression in Fibrotic ILD - Radiology Expert Excerpt
Meet-the-Expert with Dr. Oliver Distler: Highlights Report
Meet-the-Expert with Dr. Hoffmann-Vold: Highlights Report
Meet-the-Expert with Dr. Martin Aringer: Highlights Report

RELATED CONTENT